DJIA 17,042.90 -28.32 -0.17%
NASDAQ 4,493.39 -12.46 -0.28%
S&P 500 1,972.29 -5.51 -0.28%
market minute promo

Revance Therapeutics, Inc (NASDAQ: RVNC)

19.33 -1.66 (-7.91%)

Quote as of

Extended Hours: $19.33 $0.00 (-0.02%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

RVNC $19.33 -7.91%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $20.93
Previous Close $20.99
Daily Range $19.10 - $20.93
52-Week Range $18.82 - $39.86
Market Cap $454.1M
P/E Ratio -3.03
Dividend (Yield) $0.00 (0.0%)
Volume 197,330
Average Daily Volume 159,745
Current FY EPS -$3.02



Revance Therapeutics, Inc (RVNC) Description

Revance Therapeutics, Inc Website:

News & Commentary

Biotech 101: Valuing Binary Events

Sarepta Therapeutics, Revance Therapeutics, and Cytokinetics saw big moves recently; MannKind and Orexigen could be next.

Foam-focused acne fighter Foamix Pharmaceuticals sets terms for $65 million IPO

These 2 Stocks Could Be Winners Because Plenty Of People Want To Look Younger

Revance Therapeutics' (RVNC) CEO Dan Browne on Q2 2014 Results - Earnings Call Transcript

Baron Funds Comments on Revance Therapeutics Inc

US Stock Futures Flat Ahead Of Jobless Claims

This Week in Biotech: Is This the Return of Big M&A?

Merger and acquisition deals and rumors were the talk of the town this week, while three additional clinical and filing updates led to double-digit percentage moves.

Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape

Why GW Pharmaceuticals, Revance Therapeutics, and Allergan Are Today's 3 Best Stocks

M&A activity sends the S&P 500 decisively higher as GW Pharmaceuticals, Revance Therapeutics, and Allergan all jump by double digits.

Why Revance Therapeutics Inc. Shares Are Sitting Pretty

Revance shares are looking good after reporting positive phase 1/2 study data on RT002. Find out what investors should do based on this news.

See More RVNC News...